Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of Camrelizumab plus concurrent chemotherapy as
neoadjuvant approach for patients with opearble esophageal squamous cell carcinoma. In
addition, potential clinical utility of ctDNA in monitoring tumor burden and dynamics of
tumor clonality during neoadjuvant immunotherapy will be assessed as well. At the same time,
CD8 and PD-L1 will also be used as monitoring indicators.